Comparison of the most effective GLP-1 medications for weight loss: mechanism of action, clinical trial results, prices and availability in Ukraine — with DOZA online medical supervision.
The revolution in obesity treatment began with the emergence of GLP-1 agonists — medications that mimic the action of a natural gut hormone. Instead of strict diets and exhausting workouts, these drugs affect the brain's hunger center, reducing appetite naturally.
In 2026, three generations of weight loss medications are available:
Ozempic (semaglutide) — targets one GLP-1 receptor. Efficacy up to −15% body weight.
Mounjaro (Eli Lilly) — GLP-1 + GIP (tirzepatide). Efficacy up to −22.5% body weight (SURMOUNT-1).
Retatrutide — GLP-1 + GIP + glucagon. New generation with results up to −24%.
Cagrilintide — a separate pathway from GLP-1. Combines for synergy −22.7%.
All these medications are administered once a week by subcutaneous injection using a convenient pen injector. No daily pills — just one application per week.
Detailed review of each weight loss medication available in Ukraine through DOZA
⭐ Most EffectiveThe most powerful weight loss medication on the market. Tirzepatide simultaneously targets two receptors — GLP-1 and GIP, providing record weight loss among all available drugs.
🌍 Most Well-KnownThe first GLP-1 medication to become widely known for weight loss. Semaglutide suppresses appetite and slows gastric emptying, providing stable weight reduction.
Product by UNIKKA PHARMA (Brazil), distributed by Biopell Medical. Claims tirzepatide as the active ingredient but has no own clinical trials and is not registered by any regulator. Eli Lilly states it does not supply API to third-party manufacturers.
🚀 New GenerationNew-generation medication with a triple mechanism of action. Retatrutide targets three receptors simultaneously, demonstrating the highest efficacy in clinical trials.
🔗 Combines with GLP-1Long-acting amylin analog — a separate appetite control pathway from GLP-1. Key advantage: combines with Mounjaro or Ozempic for synergistic effect (CagriSema −22.7%).
All 5 medications in one table — choose based on your goals and budget
| Parameter | Mounjaro | Ozempic | Biopatid | Retatrutide | Cagrilintide |
|---|---|---|---|---|---|
| Mechanism of Action | GLP-1 + GIP | GLP-1 | Claims GLP-1 + GIP | GLP-1 + GIP + glucagon | Amylin analog |
| Weight Loss | up to −22.5% | up to −15% | No own data | up to −24% | −10.8% (mono) |
| Combination | — | — | — | — | −22.7% (CagriSema) |
| Frequency | 1x/week | 1x/week | 1x/week | 1x/week | 1x/week |
| Manufacturer | Eli Lilly | Novo Nordisk | UNIKKA PHARMA (Brazil) | Eli Lilly | Novo Nordisk / PeptoLabs |
| Status | FDA + EMA | FDA + EMA | Not registered | Phase III | Phase III |
| Availability | In Stock | In Stock | Check availability | In Stock | In Stock |
* Weight loss data: SURMOUNT-1 (tirzepatide 15 mg, 72 weeks), STEP-1 (semaglutide 2.4 mg/week — Wegovy dose; Ozempic max 2 mg for T2D), Phase II (retatrutide), Phase II (cagrilintide mono — Lancet 2021), REDEFINE-2 (CagriSema — Lancet 2024). Biopatid claims tirzepatide as active ingredient but has no own clinical trials and is not FDA/EMA registered. Individual results may vary.
The choice depends on your goals, health status and budget. Here is a general guide:
Recommendation: Mounjaro. Maximum efficacy for significant weight loss. Dual mechanism of action ensures stable results. Ideal choice when the priority is maximum results.
Recommendation: Ozempic. For moderate weight loss, Ozempic (semaglutide) by Novo Nordisk is a proven option with FDA/EMA approval and STEP-1 evidence base. If you need a stronger effect — consider Mounjaro.
Buy Ozempic in Ukraine →
Recommendation: individual Mounjaro dose. Mounjaro is available not only as KwikPen pens, but also per-dose — from 1 mg. This allows starting the program with minimal costs using a clinically proven original by Eli Lilly. Biopatid has a lower starting price, but at working doses the cost per mg is comparable, and the product has no clinical trials.
Recommendation: Retatrutide. New-generation medication with triple mechanism. Maximum results in clinical trials. For those who want the most modern approach.
Recommendation: Cagrilintide. Amylin analog — acts through a receptor separate from GLP-1. Can be combined with Mounjaro or Ozempic. Ideal for those for whom GLP-1 monotherapy doesn't provide sufficient results.
Buy Amylin in Ukraine →Not sure which medication to choose? A DOZA specialist will help select the optimal option.
Get a ConsultationGLP-1 agonists are among the most researched medications of the past decade. Mounjaro and Ozempic have undergone large-scale clinical trials with tens of thousands of participants and received FDA and EMA approval.
⚠️ This information is for educational purposes only. We recommend consulting a specialist before starting a program. Results may vary depending on individual characteristics.
Answers to the most common questions about GLP-1 medications
In 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
According to clinical data, Mounjaro (tirzepatide) is the most effective among available options: up to −22.5% body weight (SURMOUNT-1 study). Retatrutide shows even higher results (up to −24%), but is still in clinical trial stages. Learn more about Mounjaro
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
